5.7 C
Glasgow
Thursday, January 15, 2026
spot_img

More News

Trenchant BioSystems shows reduction of CGT manufacturing times to 2.5 days

Jim Cornall -
Trenchant BioSystems Inc., a CGT manufacturing platform developer for gene-modified cells, has announced multiple internal and independent external data...

DISCO Pharmaceuticals enters licence agreement with Amgen on cancer

Jim Cornall -
DISCO Pharmaceuticals has announced an exclusive license agreement with Amgen to advance novel therapeutic candidates addressing a target that...

Researchers uncover axonal protein synthesis defect in ALS

Jim Cornall -
Researchers at VIB and KU Leuven in Belgium have identified a molecular process that allows motor neurons to maintain...

Circio and University of Texas Medical Branch to evaluate circVec for treating infectious diseases

Jim Cornall -
Circio Holding ASA, a biotechnology company developing novel circular RNA expression technology for gene and cell therapy, and The...

Aragen launches platform for DNA to IND-enabling clinical supply

Jim Cornall -
Aragen has launched CHOMax, a new cell line development and early manufacturing platform that supports an integrated path from...

Base to Base biotech podcast 41: Eyes, mitochondria and a growing hub

Jim Cornall -
This week, on the first podcast of 2026, we’re talking about eye treatments with Oculis CEO, Riad Sherif, we...

Discovery could lead to new treatments for drug-resistant fungal infections

Jim Cornall -
Fungal infections kill millions of people each year, and modern medicine is struggling to keep up. But researchers at...

LoQus23 Therapeutics nominates first-in-class oral drug candidate for Huntington’s disease

Jim Cornall -
LoQus23 Therapeutics Ltd. has nominated, and is progressing, LQT-23, a drug candidate with the potential to slow or stop...

Earendil Labs to collaborate with Sanofi on bispecific antibodies for autoimmune diseases

Jim Cornall -
Earendil Labs has announced a strategic collaboration with Sanofi to apply Earendil's discovery platform to multiple autoimmune and inflammatory...

Insilico Medicine announces $888m collaboration with Servier

Jim Cornall -
Insilico Medicine, an artificial intelligence (AI)-driven drug discovery company, has announced a multi-year R&D collaboration with Servier, an independent...

Small chip predicts drug side effects and acute kidney injury

Jim Cornall -
Rhabdomyolysis is a condition in which muscle damage—often caused by drug intake—can lead to impaired kidney function and acute...

Awakening dormant immune cells inside tumours to attack cancer​

Jim Cornall -
Within tumours in the human body, there are immune cells (macrophages) capable of fighting cancer, but they have been...

CRISPR screen reveals genes required for brain development and a new neurodevelopmental disorder

Jim Cornall -
An international research team has identified hundreds of genes essential for the development of brain cells, including one gene...

Osaka looks to become global life sciences hub

Jim Cornall -
With world-class research institutions, a robust industry cluster, a strong environment for international collaboration, and comprehensive business support, the...

Positive data moving breast cancer trial forward

Jim Cornall -
Swedish company Affibody AB has announced that the Trial Review Committee (TRC) has recommended to advance the phase I...

Engineering dendritic cells boosts cancer immunotherapy

Jim Cornall -
Cancer immunotherapy is a strategy that turns the patient’s own immune cells into a “search-and-destroy” force that attacks the...

Ambros Therapeutics launches with $125m to take on complex regional pain syndrome type 1

Jim Cornall -
Ambros Therapeutics, Inc. has launched as a clinical-stage biotechnology company advancing late-stage therapies for severe, underserved diseases beginning with...

ADEL and Sanofi sign $1.04bn licence agreement for Alzheimer’s therapy

Jim Cornall -
ADEL, Inc. has entered into an exclusive worldwide license agreement with Sanofi for the development and commercialization of ADEL-Y01,...

Aukera Therapeutics emerges from stealth

Jim Cornall -
Aukera Therapeutics, a preclinical-stage biotech spin-off from the University of Basel, is officially coming out of stealth as it...

FDA clears allogeneic CAR-T recurrent glioblastoma therapy for phase II trial

Jim Cornall -
T-MAXIMUM Pharmaceutical’s proprietary allogeneic B7-H3-targeted CAR-T therapy, MT027, has received IND Clearance from the U.S. Food and Drug Administration...

Platform to test new cancer treatments

Jim Cornall -
Overcoming acquired treatment resistance is one of the major challenges in the fight against cancer. While combination therapies hold promise,...

Deeptech Digest is your guide to what's new in at the cutting edge of science technology. A bit of artificial intelligence, some biotech, and all the news and latests developments in the field. If it's deeptech, it's in Deeptech Digest!

Contact us: jim@deeptechdigest.com

© 2023 Ayr Coastal Media